|
Market Closed -
Nasdaq
06:00:00 09/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 57.67 USD | -2.27% |
|
+1.37% | +31.58% |
| 09/09 | Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11:00 AM | |
| 01/09 | Exelixis Wins Appeal in Patent Case Against MSN Laboratories | MT |
Company Valuation: Exelixis, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,784 | 5,174 | 7,460 | 9,510 | 11,799 | 14,290 | - | - |
| Change | - | -10.54% | 44.19% | 27.47% | 24.07% | 21.11% | - | - |
| Enterprise Value (EV) 1 | 4,317 | 3,865 | 6,465 | 8,399 | 10,740 | 13,545 | 12,667 | 11,542 |
| Change | - | -10.45% | 67.25% | 29.91% | 27.88% | 26.12% | -6.48% | -8.88% |
| P/E | 25.4x | 28.6x | 36.9x | 18.9x | 15.8x | 17.8x | 14.7x | 11.3x |
| PBR | 2.64x | 2.09x | 3.21x | 4.18x | 5.32x | 5.49x | 4.03x | 2.99x |
| PEG | - | -1.3x | 2.3x | 0x | 0.3x | 1.1x | 0.7x | 0.4x |
| Capitalization / Revenue | 4.03x | 3.21x | 4.08x | 4.39x | 5.09x | 5.6x | 4.93x | 4.39x |
| EV / Revenue | 3.01x | 2.4x | 3.53x | 3.87x | 4.63x | 5.31x | 4.37x | 3.55x |
| EV / EBITDA | 14.4x | 17.4x | 32.9x | 13.3x | 11.9x | 12.4x | 10x | 7.24x |
| EV / EBIT | 15.1x | 19.2x | 37.8x | 13.9x | 12.3x | 13.1x | 9.91x | 7.34x |
| EV / FCF | 12.8x | 17.2x | 22.1x | 12.5x | 12.3x | 16.4x | 15.6x | 8.3x |
| FCF Yield | 7.8% | 5.8% | 4.53% | 8% | 8.15% | 6.1% | 6.41% | 12.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | 3.238 | 3.914 | 5.119 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | 2,553 | 2,901 | 3,253 |
| EBITDA 1 | 300.3 | 222.4 | 196.6 | 633.4 | 901.2 | 1,093 | 1,261 | 1,595 |
| EBIT 1 | 286.7 | 201.5 | 170.9 | 604.6 | 872.2 | 1,032 | 1,278 | 1,572 |
| Net income 1 | 231.1 | 182.3 | 207.8 | 521.3 | 782.6 | 820.7 | 1,012 | 1,248 |
| Net Debt 1 | -1,467 | -1,308 | -995.3 | -1,111 | -1,059 | -744.5 | -1,623 | -2,747 |
| Reference price 2 | 18.28 | 16.04 | 23.99 | 33.30 | 43.83 | 57.67 | 57.67 | 57.67 |
| Nbr of stocks (in thousands) | 316,397 | 322,561 | 310,974 | 285,579 | 269,203 | 247,782 | - | - |
| Announcement Date | 17/2/22 | 7/2/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.81x | 5.31x | 12.39x | -.--% | 14.29B | |
| 20.31x | 7.19x | 14.43x | 1.46% | 69.19B | |
| 35.78x | 9.33x | 28.47x | 0.04% | 62.97B | |
| -76.45x | 14.75x | -71.13x | -.--% | 27.27B | |
| -14.89x | 5.5x | -6.92x | -.--% | 24.78B | |
| 29.76x | 6.36x | 16.51x | -.--% | 25.8B | |
| 27.41x | 5.13x | 17.28x | -.--% | 20.11B | |
| 52.99x | 19.62x | 39.8x | 0.28% | 18.47B | |
| 1285.53x | 37.11x | 809.82x | -.--% | 14.88B | |
| -14.76x | 3321.87x | -16.98x | -.--% | 13.79B | |
| Average | 136.35x | 343.22x | 84.37x | 0.18% | 29.15B | |
| Weighted average by Cap. | 77.78x | 166.95x | 48.63x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EXEL Stock
- Valuation Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
